Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Medicare targets popular weight loss drugs Ozempic, Wegovy
Sweeping review suggests weight-loss drugs’ effect on 175 conditions
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected but contain surprises, too.
Popular weight-loss drugs linked to new health risks and benefits
Researchers have found links to multiple new benefits – and new side effects – in a study of weight-loss drugs such as Ozempic and Wegovy.
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
10h
on MSN
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
12h
on MSN
Popular weight-loss drugs linked to cognitive benefits but may pose kidney risks
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a study ...
3d
E-sellers of compounded weight-loss drugs fail to reveal risks, research shows
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
IFLScience
12h
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Presidency of Donald Trump
Wegovy
drugs
Sweeping
Feedback